APRE

Healthcare Biotechnology

Aprea Therapeutics, Inc.

$0.66

-0.04 -5.53% today Live

Price History

Not enough data

Price chart data
Date	Price
Oct 5, 2026, live at 11:59 AM ET	0.66

Key Stats

Market Cap

8.33M

Avg Volume

268,229

EPS

-$0.95

52W High

$1.69

52W Low

$0.55

Div. Yield

0.0%

Analyst Ratings

Buy

Str Buy

Buy

Hold

Sell

Str Sell

Valuation

Forward P/E

-1.95

P/B Ratio

0.21

P/S Ratio

1606.13

EV/EBITDA

2.41

EV/Revenue

-6124.44

Margins

Gross Margin 0.0%

Operating Margin (255025.5%)

Net Margin 0.0%

EBITDA Margin 0.0%

Growth & Returns

Return on Equity

(46.1%)

Return on Assets

(27.7%)

Liquidity & Leverage

Current Ratio

13.55

Quick Ratio

13.33

Total Cash

41.23M

Total Debt

About

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

aprea.com